Top 2 Companies in the Global Radiodermatitis Market in 2025

The global radiodermatitis market is projected to expand at a CAGR of 3.70% during the forecast period from 2025 to 2034. Radiodermatitis is one of the frequent side effects of cancer treatment (especially breast, head, and neck cancers) or interventional radiology. The market is seeing a significant rise with an increasing number of people being affected by cancer and hence increased use of radiotherapy for treatment, proportionally influencing the radiodermatitis market. There is an increase in demand for the elimination of therapy-related side effects, which also works in favour of the radiodermatitis market. North America is expected to be the leading region of this market due to the increasing prevalence of cancer in the United States. Increasing public and private investments in the Asia Pacific region is also predicted to help the radiodermatitis market grow. The other regional market for the product includes Europe, Latin America, the Middle East, and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The expanding number of public and private healthcare organisations actively striving to improve awareness about radiodermatitis management and treatment is one of the high impact rendering elements for this sector. Furthermore, these organisations provide guidelines and recommendations on how to effectively treat the ailment, which is projected to boost the industry's growth potential throughout the forecast period. The expanding number of clinical trials being conducted to examine the efficacy of a wide range of radiodermatitis therapy items is likely to expand the market's product pipeline.BMG Pharma S.p.A.

Top Global Radiodermatitis Companies:

1. BMG Pharma S.p.A.

BMG Pharma is an Italy-based B2B biotech company that operates as a pharmaceutical company and supports oral care, dermatology, and supportive cancer care. BMG has developed numerous patented products and functional ingredients to address specific needs by out-licensing its products to a global network of partners.

2. Stratpharma AG

Stratpharma AG is one of the most formidable players in the radiodermatitis treatment market. The company specialises in the development and commercialisation of medical devices for dermatology, plastic surgery, burns, wounds, and scar management. Stratpharma is extending its focus by developing a range of innovative products for topical dermatology. These new products will extend upon the immediate focus on the scar and late stage wound healing.